New research indicates that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop conventional lifestyle programs.
Findings released in a leading health publication points out that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing such medications need to be aware of the potential of quick rebound weight gain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment weight in about a year and a half.
Weighing Approaches
The analysis, which reviewed dozens of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers note that people who lose weight through diet and exercise generally have a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Fast Regain
Experts suggest the mechanism of the jabs accounts for the accelerated weight return.
These medications imitate a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 levels far above than normal could lead to the body to produce less of its own natural GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement leads to hunger is uncontrolled, making excessive eating a significant risk."
A Chronic Issue?
The NHS suggest the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, given the significant potential of weight regain, the therapy is often life-long.
This opinion is echoed by pharmaceutical companies, who note that the findings "emphasize the persistent nature of excess weight," similar to managing conditions like hypertension.
Patient Experiences
People who have come off the jabs describe a sudden return of appetite.
"It felt as if a trigger flipping and I was suddenly extremely hungry," described an individual.
This challenge is worsened if individuals have not established lasting dietary or behavioural modifications during treatment.
Significant Use
Survey data suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is higher among females than males.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
Ultimately, researchers stress that while these medications are potent tools for weight loss, they are not a magic fix and lasting health benefits hinges on ongoing lifestyle changes.
